Access To Medicine Foundation

Often searched

Index ranking

Vacancies

10 year analysis

  • Healthcare inequity
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
    • How big is the problem?
    • How we drive change
    • Our story
    • Our impact
  • Become a catalyst
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
    • Investors
    • Companies
    • Government & policymakers
    • Events & engagements
  • Sectors and research
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
    • R&D-based pharma companies
    • Medical gas companies
    • Generic medicine manufacturers
    • Diagnostics companies
    • Vaccine manufacturers
    • Research hub
    • Company profiles & report cards
  • Cross-Sector Programmes
    • Antimicrobial resistance
    • Diabetes care
    • Antimicrobial resistance
    • Diabetes care
  • On the pulse of global health
    • Access insights
    • The Health Equity podcast
    • Access insights
    • The Health Equity podcast
  • News
  • Our team
  • Featured insights
  • Governance & financials
  • Vacancies
  • Media coverage
  • FAQ
  • Contact us

2017 Methodology for the 2018 Antimicrobial Resistance Benchmark

This methodology is the first independent framework for evaluating how pharmaceutical companies are taking action to limit AMR. It was developed in consultation with stakeholders and experts in the field and is funded by UK AID and the Dutch Ministry of Health, Welfare and Sport.

Date

23 August 2017

Download this publication

Antimicrobial resistance (AMR) is a widely recognised and growing problem. Without effective antimicrobials, infections become more difficult to treat, while medical and surgical procedures can become high-risk interventions, leading to prolonged sickness, disability and death. AMR already causes more than 700,000 deaths each year worldwide. The push to limit AMR requires a consolidated, concerted effort by multiple stakeholders, including governments, public health authorities, international health organisations, academic institutions and pharmaceutical companies.

There is growing recognition of the need for consensus on the responsibilities of each stakeholder engaged in addressing AMR, as well as the need for new, independent tools for tracking progress. The Access to Medicine Foundation has responded to this need, drawing on its expertise in developing industry metrics related to public health. The Foundation has developed the Antimicrobial Resistance Benchmark, the first independent and public tool for measuring how pharmaceutical companies are responding to AMR.

The goal of the Benchmark is to incentivise pharmaceutical companies to implement effective actions for tackling the problem of AMR. In the coming months, the Foundation will use this methodology to map the responses of a cross-section of the pharmaceutical industry to AMR, benchmarked against the consensus view on where they can and should be making progress.

Access to Medicine Foundation

Interested in our work?

Access to Medicine Foundation is funded by

Terms & conditions

Privacy & cookie policy

Disclaimer

Copyright 2004 - 2025 Access to Medicine Foundation - All Rights Reserved